On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss caused by variants of the otoferlin (OTOF) gene.

The New England Journal of Medicine published the report. The annual American Academy of Otolaryngology-Head and Neck Surgery meeting presented the data.

These latest results from the pivotal CHORD trial show 11 out of 12 participants have experienced clinically meaningful hearing improvements. This includesthree who achieved normal hearing levels.

Additionally, eight participants with longer follow-up showed stability or continued improvement in their hearing, and among the three who completed speech assessments, all showed significant improvement.

Also Read: Regeneron’s Libtayo Gains ...